Physician profile
Bruce Ourieff
NPI 1396780623
$1,377.86
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $705 · 2020: $504 · 2021: $170.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $374.99 | 2019-2021 | |
| Abbott Laboratories | $134.22 | 2021 | |
| Janssen Pharmaceuticals, INC | $132.86 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $100.24 | 2019-2021 | |
| Amarin Pharma, INC. | $98.55 | 2019 | |
| Asahi Intecc USA, INC. | $92.14 | 2020 | |
| Pfizer INC. | $77.03 | 2019-2020 | |
| Biosense Webster, INC. | $64.91 | 2019 | |
| Boston Scientific Corporation | $62.83 | 2019 | |
| Medtronic Vascular, INC. | $41.66 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $40.71 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.79 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $36.27 | 2019 | |
| Sanofi-Aventis U.S. LLC | $23.03 | 2019 | |
| Arbor Pharmaceuticals, INC. | $19.01 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $17.47 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.13 | 2020 | |
| Getinge USA Sales, LLC | $12.02 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Ourieff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.